Xilio Therapeutics, Inc. (XLO) earnings
XLO earnings moved a median of -0.88% by the close. Quarterly and annual XLO reports and results, each read against the price at its own news timestamp. Back to the XLO overview →
24 measured XLO earnings events.
Where these XLO earnings landedvs 22 measured XLO earnings reactions
| Middle 50% of XLO earnings reactions | -10.63% to +1.22% |
|---|---|
| Median reaction (to close) | -0.88% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 XLO earnings events with a measured close landed between -10.63% and +1.22%; 27% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Xilio Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -1.42% | |
| Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates | Press release | +0.00% | -1.42% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.39% | +0.00% | |
| Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates | Press release | -0.39% | +0.00% | |
| Form 10-K Xilio Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.00% | -1.63% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.67% | — | |
| Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results | Press release | -0.67% | — | |
| Form 10-Q Xilio Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -4.79% | -0.34% | |
| Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results | Press release | -4.79% | -0.34% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.41% | +0.00% | |
| Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results | Press release | +4.23% | +8.74% | |
| Form 10-K Xilio Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -4.79% | -4.52% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -25.20% | -18.11% | |
| Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results | Press release | -25.20% | -18.11% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.40% | +1.63% | |
| Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results | Press release | +2.40% | +1.63% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.77% | +2.83% | |
| Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results | Press release | +3.77% | +2.83% | |
| Form 10-K Xilio Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | +4.22% | |
| Form 10-K/A Xilio Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | — | -10.63% | |
| Form 10-Q Xilio Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | — | -10.63% | |
| Form 10-Q/A Xilio Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | — | -10.63% | |
| Form 10-Q/A Xilio Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | — | -10.63% | |
| Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results | Press release | — | -10.63% |
Keep exploring
More XLO: analyst actions → · SEC filings → · XLO overview →